<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04849260</url>
  </required_header>
  <id_info>
    <org_study_id>ZKAB001-LEES-2019-02</org_study_id>
    <nct_id>NCT04849260</nct_id>
  </id_info>
  <brief_title>Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma</brief_title>
  <official_title>Phase Ib/II, Open Label, Controlled Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma After First-line Treatment Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be divided into two stages: phase Ib and phase II. The safety and phase II&#xD;
      recommended dose (RP2D) of Pexa-Vec combined with ZKAB001 in patients with local progression&#xD;
      of failed first-line treatment or metastatic melanoma will be evaluated in phase Ib.&#xD;
&#xD;
      Objective response rate (ORR) and progression-free survival (PFS) of ZKAB001 combined with&#xD;
      RP2D's Pexa-Vec or ZKAB001 monotherapy in patients with local progression or metastatic&#xD;
      melanoma will be evaluated in phase II.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be divided into two stages: phase Ib and phase II. The safety and phase II&#xD;
      recommended dose (RP2D) of Pexa-Vec combined with ZKAB001 in patients with local progression&#xD;
      of failed first-line treatment or metastatic melanoma will be evaluated in phase Ib.&#xD;
&#xD;
      Objective response rate (ORR) and progression-free survival (PFS) of ZKAB001 combined with&#xD;
      RP2D's Pexa-Vec or ZKAB001 monotherapy in patients with local progression or metastatic&#xD;
      melanoma will be evaluated in phase II.&#xD;
&#xD;
      The study is also going to evaluate the combination therapy or monotherapy:&#xD;
&#xD;
        1. overall survival time ((OS)), disease control rate (DCR) and duration of remission (DOR)&#xD;
           in patients with metastatic melanoma.&#xD;
&#xD;
        2. safety&#xD;
&#xD;
        3. the relationship between the expression of PD-L1 in tumor tissue and clinical effect；&#xD;
&#xD;
        4. the changes of immune microenvironment (CD8+ expression) in tumor tissue before and&#xD;
           after Pexa-vec treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dose-limited toxicity (DLT)</measure>
    <time_frame>28 days after first dose</time_frame>
    <description>dose-limited toxicity (DLT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>maximum tolerated dose (MTD)</measure>
    <time_frame>28 days after first dose</time_frame>
    <description>recommended phase 2 dose RP2D.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>progression free survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>2 years</time_frame>
    <description>objective response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease control rate (DCR)</measure>
    <time_frame>2 years</time_frame>
    <description>disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response (DOR)</measure>
    <time_frame>2 years</time_frame>
    <description>duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month and 1-year PFS rate</measure>
    <time_frame>12 months</time_frame>
    <description>6-month and 1-year PFS rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year and 2-year OS rates</measure>
    <time_frame>2 years</time_frame>
    <description>1-year and 2-year OS rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE/SAEs</measure>
    <time_frame>2 years</time_frame>
    <description>The incidence and severity of adverse events (AE) and severe adverse events (SAE).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Local Progression or Metastatic Melanoma With Failed First-line Treatment</condition>
  <arm_group>
    <arm_group_label>Pexa-Vec combined with ZKAB001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The combined treatment group is divided into two dose groups. The principle of &quot;3+3&quot; is adopted to determine RP2D, and RP2D will be used in subsequent patients in this cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZKAB001 monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ZKAB001 monotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pexa-Vec combined with ZKAB001</intervention_name>
    <description>Intratumoral injection of low dose Pexa-Vec (3×10^8pfu) combined with intravenous of ZKAB001 (5mg/kg), every 2 weeks as one cycle.&#xD;
Intratumoral injection of high dose Pexa-Vec (1×10^9pfu) combined with intravenous of ZKAB001 (5mg/kg), every 2 weeks as one cycle.</description>
    <arm_group_label>Pexa-Vec combined with ZKAB001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ZKAB001 monotherapy</intervention_name>
    <description>ZKAB001 monotherapy</description>
    <arm_group_label>ZKAB001 monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary signing of informed consent.&#xD;
&#xD;
          2. Age 18-75 years old (inclusive), regardless of gender.&#xD;
&#xD;
          3. Pathologically proved to be malignant melanoma, including skin, mucous membrane, and&#xD;
             limb origin, and locally progressive or metastatic melanoma that cannot be completely&#xD;
             resected.&#xD;
&#xD;
          4. The patient has more than 1 superficial focus for intratumoral injection (suitable for&#xD;
             direct or ultrasound-guided injection), which can be skin, subcutaneous or lymph node&#xD;
             focus, the longest diameter is (LD) ≥ 1cm and ≤ 10cm, and there is no ulcer in the&#xD;
             injected focus.&#xD;
&#xD;
          5. Patients who have failed to receive first-line treatment of melanoma in the past,&#xD;
             including chemotherapy and targeted therapy.&#xD;
&#xD;
             Systemic anticancer therapy or adjuvant therapy must be completed at least 4 weeks&#xD;
             before enrollment (if previously received nitrosourea or mitomycin C chemotherapy, the&#xD;
             interval between the end of chemotherapy and the study group is more than 6 weeks).&#xD;
&#xD;
             Patients with adverse events caused by previous treatment recovered to ≤ CTCAE level&#xD;
             1, except for hair loss.&#xD;
&#xD;
          6. Based on RECIST 1.1, imaging evaluation confirmed that there was an assessable focus&#xD;
             (except for one measurable lymph node focus).&#xD;
&#xD;
          7. The ECOG physical condition score is 0 or 1, and the expected survival time is more&#xD;
             than 3 months.&#xD;
&#xD;
          8. The functions of blood, liver and kidney are good and meet the results of laboratory&#xD;
             tests:&#xD;
&#xD;
        1) Absolute neutrophil count (ANC) ≥ 1.5x10^9 / L. 2) Platelet ≥ 80 × 10^9 shock L. 3)&#xD;
        Hemoglobin ≥ 90g/L. 4) Serum albumin ≥ 28g/L. 5) Bilirubin ≤ 1.5x ULN. 6) ALT and AST ≤&#xD;
        2.5x ULN, if there is liver metastasis, ALT and AST ≤ 5x ULN. 7) Serum Cr ≤ 1.25 × ULN or&#xD;
        endogenous creatinine clearance ≥ 50mL/min (using standard Cockcroft-Gault formula).&#xD;
&#xD;
        8) Coagulation function, in which INR &lt; 1.7. 9. Female or male patients of childbearing age&#xD;
        should take effective contraceptive methods during the study period and within 3 months&#xD;
        after the end of the study treatment period. Non-operative sterilization female patients of&#xD;
        childbearing age must be negative for serum or urine HCG test during the screening period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any active autoimmune disease or history of autoimmune disease (such as, but not&#xD;
             limited to, interstitial pneumonia, uveitis, enteritis, hepatitis, rheumatoid&#xD;
             arthritis, nephritis, pituitary inflammation, hyperthyroidism, hypothyroidism, etc.);&#xD;
             subjects with vitiligo or childhood asthma still need medical intervention after&#xD;
             adulthood.&#xD;
&#xD;
             Asthma in which subjects need bronchodilators for medical intervention.&#xD;
&#xD;
          2. Subjects were treated with immunosuppressants or systemic or absorbable local&#xD;
             corticosteroids within 2 weeks before enrollment to achieve immunosuppression (dose &gt;&#xD;
             10mg/ prednisone or equivalent).&#xD;
&#xD;
          3. Has received or plans to receive any form of organ transplant, including allogeneic&#xD;
             stem cell transplantation.&#xD;
&#xD;
          4. Known to be allergic to macromolecular protein preparations, or to any composition of&#xD;
             ZKAB001 and Pexa-Vec.&#xD;
&#xD;
          5. Severe allergic reactions or side effects occurred in the past vaccination process.&#xD;
&#xD;
          6. If you have other malignant tumors at the same time, the survival without progression&#xD;
             or recurrence should be more than 3 years.&#xD;
&#xD;
          7. Subjects with known active central nervous system (CNS) metastasis and / or&#xD;
             carcinomatous meningitis.&#xD;
&#xD;
             Note: subjects who have previously received brain metastasis treatment and subjects&#xD;
             with clinically stable CNS metastasis may be allowed to participate in the study&#xD;
             (defined as at least 4 weeks before the first dose of the trial treatment: (1) No new&#xD;
             or expanded evidence of CNS metastasis (through MRI); (2) subjects have been treated&#xD;
             without hormones for at least 2 weeks; (3) any neurological symptoms have returned to&#xD;
             baseline levels.&#xD;
&#xD;
          8. Patients with uncontrolled cardiac clinical symptoms or diseases, such as heart&#xD;
             failure above NYHA2, unstable angina pectoris, myocardial infarction within 1 year,&#xD;
             clinically significant supraventricular or ventricular arrhythmias requiring treatment&#xD;
             or intervention, left ventricular ejection fraction at rest was less than 50%.&#xD;
&#xD;
          9. After injection treatment, tumor swelling and / or necrosis may invade important&#xD;
             vascular structures (such as carotid artery) or other important anatomical sites (such&#xD;
             as spinal cord).&#xD;
&#xD;
         10. A history of severe inflammatory skin diseases requiring drug treatment and a history&#xD;
             of severe eczema requiring drug treatment (confirmed by researchers).&#xD;
&#xD;
         11. The subjects had active infection, or had a fever of unknown origin during the&#xD;
             screening period or within a week before the first administration of the drug &gt; 38.5&#xD;
             ℃. (according to the judgment of the researchers, the fever caused by the tumor can be&#xD;
             included in the group.).&#xD;
&#xD;
        twelve。 Active hepatitis B or C (unless HBV-DNA titer &lt; 500IU/mL or copy number &lt;&#xD;
        1000copies/ml, HCV-RNA negative can be included in), HIV [G1] positive or known history of&#xD;
        acquired immunodeficiency syndrome after antiviral treatment.&#xD;
&#xD;
        13. Subjects are participating in other clinical studies, or less than one month from the&#xD;
        end of the previous clinical study, except for non-interventional clinical studies (such as&#xD;
        epidemiological studies).&#xD;
&#xD;
        14. HCV therapy could not be stopped within 14 days before Pexa-Vec injection. If a patient&#xD;
        is using any antiviral drugs, he or she should consult the researcher to determine whether&#xD;
        the patient is suitable to participate in the study.&#xD;
&#xD;
        15. Less than 4 weeks from the previous use of immune checkpoint inhibitors, such as&#xD;
        PD-1/CTLA-4 inhibitors (that is, more than 4 weeks from the previous receipt of PD-1/CTLA-4&#xD;
        inhibitors); or have been treated with other oncolytic viruses (such as T-Vec, recombinant&#xD;
        human GM-CSF herpes simplex virus injection (OrienX010), etc.) or PD-L1 inhibitors.&#xD;
&#xD;
        16. The patients were vaccinated with live vaccine within 4 weeks before screening.&#xD;
&#xD;
        Inactivated vaccines to prevent influenza and inactivated vaccines to prevent other&#xD;
        infectious diseases can be used on a case-by-case basis, but it is necessary to consider&#xD;
        increasing the elution period before and after medication.&#xD;
&#xD;
        17. Subjects are known to have a history of psychotropic substance abuse, alcohol abuse or&#xD;
        drug use.&#xD;
&#xD;
        18. Have a history of pulmonary tuberculosis. 19. The researchers evaluated that there was&#xD;
        a significant bleeding event in the previous 12 months and the risk of intratumoral&#xD;
        injection procedure increased.&#xD;
&#xD;
        20. Pregnant or lactating women. 21. The researchers determined that the patient had other&#xD;
        factors that might lead to the termination of the study, such as other serious diseases or&#xD;
        serious laboratory abnormalities or accompanied by other factors that would affect the&#xD;
        safety of the subjects, or family or social factors such as the collection of trial data&#xD;
        and samples.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccinia</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

